Page 319 - AIDSBK23C
P. 319
Page 319
265 Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold F, Young NS. Human
immunodeficiency virus type 1 protease inhibitor modulates activations of peripheral
blood CD4+ cells and decreases their susceptibility to apoptosis in vitro and in vivo.
Blood. 1999;94:1021-1027.
266 Mehandru S, Markowitz M. Tipranavir: a novel non-peptidic protease inhibitor for the
treatment of HIV infection. Expert Opin Investig Drugs. 2003;12:1821-1828.
267 Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
268 Rose RE, Gong YF, Greytck JA, et al. Human immunodeficiency virus type 1 viral
background plays a major role in development of resistance to protease inhibitors. Proc
Natl Acad Sci U S A. 1996;93:1648-1653.
269 Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, Falloon J.
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients
with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab.
1999;84:1925-1931.
270 Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir
and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS.
2004;18:2137-244.
271 Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human
immunodeficiency virus/acquired immunodeficiency syndrome patients: protease
inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59:816-824.
272 Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic
infections. N Engl J Med. 2001;344:984-996.
273 Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-
resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
274 Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an
overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
J Infect. 2008;57:1-10.
275 Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann
Pharmacother. 2010;44:145-156.
276 Martin DE, Salzwedel K, Allaway GP. Bevirimat: a novel maturation inhibitor for the
treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19:107-113.
277 Lapadula G, Izzo I, Gargiulo F, Paraninfo G, Castelnuovo F, Quiros-Roldan E, Cologni
